Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Diluted Average) (2016 - 2025)

Ani Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $21.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 9.89% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $21.2 million, up 9.89%, while the annual FY2025 figure was $21.2 million, 9.89% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $21.2 million at Ani Pharmaceuticals, up from $20.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $21.2 million in Q4 2025 and bottomed at $12.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $17.7 million (2023), against an average of $17.2 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) surged 35.09% in 2022 before it rose 0.78% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $12.6 million in 2021, then rose by 29.09% to $16.3 million in 2022, then grew by 11.89% to $18.2 million in 2023, then rose by 6.18% to $19.3 million in 2024, then rose by 9.89% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Shares Outstanding (Diluted Average) are $21.2 million (Q4 2025), $20.9 million (Q3 2025), and $20.3 million (Q2 2025).